Comparative study of the effects on L-dopa formulation absorption by the acid secretion inhibitor
- Conditions
- healty adult Parkinson's disease
- Registration Number
- JPRN-UMIN000016659
- Lead Sponsor
- tano National Hospital, National Hospital Organaization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 3
Not provided
1.Subjects taking H2-receptor antagonists and Proton pump inhibitors 2.Subjects with allergy for L-dopa formulation,H2-receptor antagonists and Proton pump inhibitors 3.Subjects taking drugs that have interaction with L-dopa formulation,H2-receptor antagonists and Proton pump inhibitors 4.Subjects with glaucoma 5.Subjects with liver failure or renal dysfunction 6.Subjects with gastric ulcer,duodenal ulcer or with that history 7.Diabetic 8.Subjects with serious lung disease, serious cardiovascular disease,bronchial asthma or endocrine disorder 9.Subjects with psychiatric symptoms such as suicidal tendencies 10.Dialysis patient 11.Pregnant women or women who may possibly be pregnant 12.Subjects who are judged to be inadequate to participate in this trial at the blood sampling of provisional registration 13.Others, subjects who are judged to be inadequate to participate in this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -dopa blood concentration in blood collection point of taking L-dopa formulation before, after taking 10,20,30,60,120,240 minutes when taking L-dopa formulation alone, combination with H2-receptor antagonists, combination with Proton pump inhibitors
- Secondary Outcome Measures
Name Time Method